View Item 

Show simple item record

A scoping review of clinical pharmacist and pharmacy technician contributions to cystic fibrosis care
dc.contributor.authorKim, Alexander S.
dc.contributor.authorThompson, Amy N.
dc.contributor.authorAxon, David R.
dc.contributor.authorSabourin, Ashley
dc.contributor.authorDavies, Madeleine J.
dc.contributor.authorShannon, Carol
dc.contributor.authorNasr, Samya Z.
dc.contributor.authorPhan, Hanna
dc.date.accessioned2024-01-04T22:02:33Z
dc.date.available2025-01-04 17:02:32en
dc.date.available2024-01-04T22:02:33Z
dc.date.issued2023-12
dc.identifier.citationKim, Alexander S.; Thompson, Amy N.; Axon, David R.; Sabourin, Ashley; Davies, Madeleine J.; Shannon, Carol; Nasr, Samya Z.; Phan, Hanna (2023). "A scoping review of clinical pharmacist and pharmacy technician contributions to cystic fibrosis care." Journal of the American College of Clinical Pharmacy 6(12): 1357-1365.
dc.identifier.issn2574-9870
dc.identifier.issn2574-9870
dc.identifier.urihttps://hdl.handle.net/2027.42/191941
dc.description.abstractThe purpose of this scoping literature review was to assess available published literature/abstracts, and to examine described contributions by pharmacists and/or pharmacy technicians as part of the care of people with cystic fibrosis (pwCF). This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Published abstracts and articles from inception through December 2022 were included if they described care of pwCF (all ages), with at least one group of participants receiving care/services from pharmacy staff, and were available in English. Data extractions were outcomes, study, and participant characteristics. From 756 abstracts and papers, 91 were included. The majority were published abstracts (n = 67), from the United States (n = 64), retrospective cohort study design (n = 47), involved pharmacist intervention (n = 75), with no comparison group (n = 48), and in an outpatient/ambulatory setting (n = 59). Most often, literature were descriptions of specific pharmacist services, evaluations of adding a pharmacist, or descriptions of overall pharmacist practice/role. Specific pharmacist services were defined as patient or caregiver education, adherence support, medication reconciliation, management of pulmonary exacerbations, and medication management (including monitoring, and telehealth). Pharmacists and pharmacy technicians have contributed to the care of pwCF in various ways; however, much of the available data are currently disseminated in the form of conference abstracts. Efforts to support author publication of data as full peer-reviewed publications should be prioritized as this data can help support others’ efforts to develop or support similar clinical pharmacy services.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othercystic fibrosis
dc.subject.otherpharmacy technician
dc.subject.otherpharmacists
dc.subject.otherpharmacy
dc.titleA scoping review of clinical pharmacist and pharmacy technician contributions to cystic fibrosis care
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191941/1/jac51877.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191941/2/jac51877_am.pdf
dc.identifier.doi10.1002/jac5.1877
dc.identifier.sourceJournal of the American College of Clinical Pharmacy
dc.identifier.citedreferenceRedfern J, Webb AK. Benefits of a dedicated cystic fibrosis pharmacist. J R Soc Med. 2004; 97 ( 44 ): 2 – 7.
dc.identifier.citedreferenceCystic Fibrosis Foundation. Your CF care team. https://www.cff.org/managing-cf/your-cf-care-team
dc.identifier.citedreferenceLouie JM, Hong LT, Garavaglia LR, Pinal DI, O’Brien CE. Evaluation of home medication reconciliation by clinical pharmacists for adult and pediatric cystic fibrosis patients. Pharmacy (Basel). 2018; 6 ( 3 ): 91. https://doi.org/10.3390/pharmacy6030091
dc.identifier.citedreferenceZobell JT, Schwab E, Collingridge DS, Ball C, Nohavec R, Asfour F. Impact of pharmacy services on cystic fibrosis medication adherence. Pediatr Pulmonol. 2017; 52 ( 8 ): 1006 – 1012. https://doi.org/10.1002/ppul.23743
dc.identifier.citedreferenceAbraham O, Li JS, Monangai KE, Feathers AM, Weiner D. The pharmacist’s role in supporting people living with cystic fibrosis. J Am Pharm Assoc. 2018; 58 ( 3 ): 246 – 249. https://doi.org/10.1016/j.japh.2018.01.006
dc.identifier.citedreferenceTricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018; 169 ( 7 ): 467 – 473. https://doi.org/10.7326/M18-0850
dc.identifier.citedreferenceClark JM, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y, et al. Improving the translation of search strategies using the polyglot search translator: a randomized controlled trial. J Med Libr Assoc. 2020; 108 ( 2 ): 195 – 207. https://doi.org/10.5195/jmla.2020.834
dc.identifier.citedreferenceMoher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151 ( 4 ): 264 – 269. https://doi.org/10.7326/0003-4819-151-4-200908180-00135
dc.identifier.citedreferenceLiberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Loannidi JPC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151 ( 4 ): W65 – W94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136
dc.identifier.citedreferenceMogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2013; 187 ( 7 ): 680 – 689. https://doi.org/10.1164/rccm.201207-1160OE
dc.identifier.citedreferenceLahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, et al. Clinical practice guidelines from the Cystic fibrosis foundation for preschoolers with cystic fibrosis. Pediatrics. 2016; 137 ( 4 ): e20151784. https://doi.org/10.1542/peds.2015-1784
dc.identifier.citedreferenceBorowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155 ( 6 ): S73 – S93. https://doi.org/10.1016/j.jpeds.2009.09.001
dc.identifier.citedreferenceSawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009; 8 ( 2 ): 91 – 96. https://doi.org/10.1016/j.jcf.2008.09.007
dc.identifier.citedreferenceAnstead M, Murphy D, Dvorak A, Caudill S, Kuhn R. Identifying and overcoming barriers to adherence at an adult cystic fibrosis center by the addition of a pharmacist. Pediatr Pulmonol. 2014; 49: 402.
dc.identifier.citedreferenceRoder L, Simonsen M, Fitzpatrick L, He J, Loucks J. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation. J Manag Care Spec Pharm. 2022; 28 ( 9 ): 989 – 996. https://doi.org/10.18553/jmcp.2022.28.9.989
dc.identifier.citedreferenceAbraham O, Morris A. Opportunities for outpatient pharmacy services for patients with cystic fibrosis: perceptions of healthcare team members. Pharmacy. 2019; 7 ( 2 ): 34. https://doi.org/10.3390/pharmacy7020034
dc.identifier.citedreferenceBhakta ZN, Young DC, Zobell JT, Kuhn RJ, Sabadosa KA, Chin M, et al. A survey of the pharmacist’s role at US CFF-accredited centers-a director’s perspective. Pediatr Pulmonol. 2013; 48 ( S36 ): 207 – 453.
dc.identifier.citedreferenceU.S. Department of Health and Human Services. Organ Procurement and Transplantation Network Bylaws. Virginia: Organ Procurement and Transplant Network; 2023. https://optn.transplant.hrsa.gov/media/lgbbmahi/optn_bylaws.pdf
dc.identifier.citedreferenceWiegel JJ, Olyaei AJ. The role of the pharmacist in the management of kidney transplant recipients. Indian J Urol. 2016; 32 ( 3 ): 192 – 198. https://doi.org/10.4103/0970-1591.185108
dc.identifier.citedreferenceOrgan Procurement & Transplantation Network. OPTN Bylaws. https://optn.transplant.hrsa.gov/policies-bylaws/bylaws/
dc.identifier.citedreferenceSam S, Guérin A, Rieutord A, Belaiche S, Bussières JF. Roles and impacts of the transplant pharmacist: a systematic review. Can J Hosp Pharm. 2018; 71 ( 5 ): 324 – 337.
dc.identifier.citedreferenceSpencer S, Majkowski C, Suda KJ. Predictors of publication rates for abstracts presented at the American Association of Colleges of Pharmacy annual meetings. Am J Pharm Educ. 2018; 82 ( 8 ): 6409. https://doi.org/10.5688/ajpe6409
dc.identifier.citedreferenceMiller JL, Lewis TV, Walling J, O’Donnell A, Neely SB, Johnson PN. Publication rates of pediatric-focused resident research projects presented at the Pediatric Pharmacy Association Bruce Parks Memorial Residency showcase. J Pediatr Pharmacol Ther. 2021; 26 ( 2 ): 163 – 171. https://doi.org/10.5863/1551-6776-26.2.163
dc.identifier.citedreferenceEgloff HM, West CP, Wang AT, Lowe KM, Edakkanambeth Varayil J, Beckman TJ, et al. Publication rates of abstracts presented at the Society of General Internal Medicine annual meeting. J Gen Intern Med. 2017; 32 ( 6 ): 673 – 678. https://doi.org/10.1007/s11606-017-3990-5
dc.identifier.citedreferenceAl-Yatama F, Pandis N, Cobourne MT, Seehra J. Publication rate of abstracts from presentations at the British Orthodontic Conference 2009–2014. J Orthod. 2020; 47 ( 4 ): 311 – 319. https://doi.org/10.1177/1465312520944189
dc.identifier.citedreferenceJagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, et al. The “gender gap” in authorship of academic medical literature—a 35-year perspective. New England Journal of Medicine. 2006; 355 ( 3 ): 281 – 287. https://doi.org/10.1056/NEJMsa053910
dc.identifier.citedreferenceScherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews. 2007; 18: MR000005. https://doi.org/10.1002/14651858.MR000005.pub3
dc.identifier.citedreferenceCystic Fibrosis Foundation patient registry 2021 annual data report; 2022.
dc.identifier.citedreferenceGuo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022; 21 ( 3 ): 456 – 462. https://doi.org/10.1016/j.jcf.2022.01.009
dc.identifier.citedreferenceElborn JS. How can we prevent multisystem complications of cystic fibrosis? Semin Respir Crit Care Med. 2007; 28 ( 3 ): 303 – 311. https://doi.org/10.1055/s-2007-981651
dc.identifier.citedreferenceSawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013; 12 ( 5 ): 461 – 467. https://doi.org/10.1016/j.jcf.2012.12.009
dc.identifier.citedreferenceTjugum SL, Hansen BK, McKinzie CJ. Association of medication regimen complexity with clinical endpoints in pediatric patients with cystic fibrosis. J Pediatr Pharmacol Ther. 2021; 26 ( 3 ): 248 – 252. https://doi.org/10.5863/1551-6776-26.3.248
dc.identifier.citedreferenceRen CL, Morgan RL, Oermann C, Resnick HE, Brady C, Campbell A, et al. Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis. Ann Am Thorac Soc. 2018; 15 ( 3 ): 271 – 280. https://doi.org/10.1513/AnnalsATS.201707-539OT
dc.identifier.citedreferenceYoung DC, Autry E, Zobell JT, Kormelink L, Homa K, Sabadosa KA, et al. Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. Pediatr Pulmonol. 2019; 54 ( 8 ): 1216 – 1224. https://doi.org/10.1002/ppul.24348
dc.identifier.citedreferenceBell SC, Robinson PJ. Cystic fibrosis standards of care. Australia: Cystic Fibrosis; 2008. https://thoracic.org.au/wp-content/uploads/2022/09/CF_standardsofcare_Australia_2008.pdf
dc.identifier.citedreferenceStandards for the clinical care of children and adults with cystic fibrosis in the UK: 2022 Addendum; 2011.
dc.identifier.citedreferencePharmacy standards in cystic fibrosis care in the UK: Third Edition; 2022.
dc.identifier.citedreferenceConway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, et al. European cystic fibrosis society standards of care: framework for the cystic fibrosis centre. J Cyst Fibros. 2014; 13 ( Suppl 1 ): S3 – S22. https://doi.org/10.1016/j.jcf.2014.03.009
dc.identifier.citedreferenceYankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care. Chest. 2004; 125 ( 1 ): 1S – 39S. https://doi.org/10.1378/chest.125.1_suppl.1S
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jac51877.pdf
Size:
1.096MB
Format:
PDF
View/Open
Name:
jac51877_am.pdf
Size:
523.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.